1 Evaluation of EUROSCORE II to determine the prognosis of patients with

2 moderate-to-severe aortic stenosis: a long-term retrospective study

- Xianzhen Cai^{1,2+}, Danchun Hu^{1,2+}, Baoxin Yan^{1,2}, Jinhao Chen^{1,2}, Weiwen Li^{1,2}, Ying 3
- Lin^{1,2}, Run Lin^{1,2}, Junjun Ye^{1,2}, Xiaojun Huang¹, Bin Xie¹, Xiaodong Zhuang^{3*}, 4
- 5 Jianying Chen^{4*}, Jilin Li^{1*}
- 6
- 7 ¹Department of Cardiology, Second Affiliated Hospital of Shantou University
- 8 Medical College, No. 69 North Dongxia Road, Shantou 515000, Guangdong, China
- 9 ²Shantou University Medical College, Shantou, Guangdong, China
- 10 ³Department of Cardiology, the First Affiliated Hospital of Sun Yat-Sen University,
- 11 58 Zhongshan 2nd Road, Guangzhou 510080, China
- 12 ⁴Department of Cardiology, Affiliated Hospital of Guangdong Medical University,
- 13 Zhanijang 524001, China
- 14
- 15 Author contributions
- 16 ⁺Xianzhen Cai and Danchun Hu contributed to the manuscript equally.
- 17 Xianzhen Cai
- 18 Email: 2784815878@gg.com
- 19 ⁺Danchun Hu
- 20 Email: 1074969728@gg.com
- 21 Contributor Information.
- 22 * Corresponding authors
- 23 Jilin Li
- 24 Tel: +86 754-83141133, Email: lijilin@126.com
- 25 Xiaodong Zhuang
- 26 Email: zhuangxd3@mail.sysu.edu.cn
- 27 Jianying Chen
- 28 E-mail: jychen271@126.com
- 29
- 30 **Declaration of interests**
- 31 The authors declare no competing interests.
- 32 **Data availability**
- 33 The datasets used and/or analyzed during the current study are available from the
- 34 corresponding authors upon reasonable request.
- 35 Funding
- 36 Nothing to declare.
- 37 **Ethical approval**
- 38 This study was approved by the Ethics Review Committee of the Second Affiliated
- 39 Hospital of Shantou University Medical College(ERB number: ethics form 9-5).
- 40 Patient follow-up was conducted via telephone contact, with verbal informed consent
- 41 approved by the institutional ethics committee.
- 42 **Pre-registered clinical trial number**
- 43 NOT Provise report reports new research that has ber be Certific 106 928 2 eview and should not be used to guide clinical practice.

44 Consent for publication

- 45 Not applicable.
- 46 Competing interests
- 47 The authors declare no competing interests.
- 48 Acknowledgments
- 49 We thank Mark Cleasby, PhD from Liwen Bianji (Edanz) (www.liwenbianji.cn) for
- 50 editing the language of a draft of this manuscript.
- 51
- 52 Central Message Our heart valvular disease intervention center construction unit
- from The Second Affiliated Hospital of Shantou University Medical College is part of
 the National Clinical Medical Research Center for Radiology and Therapy,
- Interventional Center for Valvular Disease, Dongfang Huaxia Cardiovascular Health
 Institute, Suzhou Industrial Park.
- 57 Our data were from Three heart valve centers, which are derived from a database
- 58 called Aortic Valve Diseases RISk facTOr assessmenT and Prognosis modeL
- 59 Construction (ARISTOTLE).
- 60

61 Glossary of Abbreviations

- 62 EuroSCORE II (European System for Cardiac Operative Risk Evaluation), SBP
- 63 (systolic blood pressure), CKD (chronic kidney disease), COPD (chronic obstructive
- 64 pulmonary disease), HB (haemoglobin), TC (total cholesterol), HDL-C (high-density
- 65 lipoprotein-cholesterol), LDL-C(low-density lipoprotein-cholesterol), TG
- 66 (triglyceride), Cr (creatinine), CC(creatinine clearance), TBIL(total bilirubin), LVEF
- 67 (left ventricular ejection fraction), AV_Vmax(maximum velocity of blood flow
- 68 through the aortic valve), AV_MG (mean gradient across the aortic valve), AVA
- 69 (aortic valve area), PAH(pulmonary arterial hypertension), ACEI (angiotensin
- 70 converting enzyme inhibitor), ARB(angiotensin receptor blocker), CCB(calcium
- 71 channel blocker), LVEF (left ventricular ejection fraction), AV_Vmax(maximum flow
- velocity through the aortic valve), AV_MG(mean gradient across the aortic valve),
- 73 AVA(aortic valve area), PAH(pulmonary arterial hypertension)

74

75 word count of the manuscript text:4158

- 76
- 77
- 78

79 Background and Aims

80	Aortic stenosis (AS) was a prevalent heart valve disease whose morbidity and
81	mortality can be reduced by aortic valve replacement (AVR) . EUROSCORE II
82	assesses the perioperative mortality of severe AS patients undergoing AVR. This study
83	explored EUROSCORE II's prognostic value for long-term all-cause mortality of
84	Chinese patients with moderate-to-severe AS and determined whether AVR affects
85	this.
86	Methods
87	Allocated to four groups following the EUROSCORE II (cut-off value of 4%) and
88	whether performed AVR, 544 patients with moderate-to-severe AS were enrolled.
89	Baseline data, Kaplan - Meier, Cox regression and subgroup analysis were used to
90	analyse the relationship between EUROSCORE II and participants' all-cause
91	mortality. Furthermore, ROC analysis determining the optimal cut-off value of
92	EUROSCORE II was utilized.
93	Results
94	During a median follow-up of 41.4 months, 177 (21.5%) participants reached the
95	endpoint, with higher risks (EUROSCORE II $\geq 4\%$) and no AVR exhibited
96	significantly increased all-cause mortality rates compared to other groups (55.4% vs.
97	6.5%, 13.4%, and 32.7%; P<0.001). Kaplan-Meier curves confirmed these findings
98	(log-rank test P<0.001). Cox regression analysis revealed a 6.891-fold higher risk
99	(HR, 6.891; 95% CI, 3.083-15.401; P<0.001) in patients without AVR with higher
100	EUROSCORE II. The adjusted model (P<0.01) and subgroup analyses (without AVR
101	P=0.001; with AVR P=0.029) supported EUROSCORE II's prognostic value for
102	all-cause mortality. The optimal EUROSCORE II cut-off for predicting all-cause
103	mortality in patients without AVR was 2.23% (AUC 0.675).

104 Conclusions

LOROBCORD If (out on value 1/0) and if it independently impact the rong term

- 106 prognosis of patients with moderate-to-severe AS.

- -

120 Keywords

- 121 Aortic valve stenosis; EUROSCORE II; all-cause mortality; aortic valve replacement
- 123 —

124 Introduction

125	Aortic stenosis (AS) is the most prevalent heart valve disease, causing significant
126	morbidity and mortality in the elderly due to aging of the population[1-3]. Its
127	prevalence exceeds 10% in individuals aged over 65 in US and European
128	populations[4-6], although the prevalence in China may be lower, according to the
129	results of a single-centre retrospective study of the echocardiographic data of 287,556
130	patients[7]. The initial stages of the disease are characterized by the progression of
131	valvular lesions, involving endothelial cell damage, infiltration with lipids and
132	macrophages, lipid oxidation, and subsequent fibrosis and calcification, which
133	ultimately leads to obstruction of the aortic valve[6,8].
134	To date, owing to the absence of specific medication for the treatment or
135	prevention of the progression of AS, surgical aortic valve replacement (SAVR) or
136	transcatheter aortic valve implantation (TAVI) are the recommended means of treating
137	patients with severe symptoms[9,10]. EUROSCORE II is a widely-used risk
138	assessment tool[11-17] that uses various characteristics of the patient to estimate the
139	risk of adverse outcomes, and it has been clinically implemented to identify high-risk
140	patients during hospitalization and predict 30-day mortality in those undergoing
141	coronary artery bypass grafting (CABG)[18], SAVR, or TAVR[19]. However, data are
142	lacking regarding the long-time prognostic value of EUROSCORE II with respect to
143	the mortality and morbidity rates of patients with moderate-to-severe AS, and whether
144	AVR (SAVR or TAVR) is associated with a superior prognosis, especially in Chinese
145	patients.
146	Consequently, the primary objective of this retrospective study was to
147	characterize the relationships of EUROSCORE II and AVR status with all-cause
148	mortality in patients with moderate-to-severe AS. In addition, we aimed to identify the

149 optimal cut-off value of EUROSCORE II for prognostic use in patients who do not

- undergo AVR.
- 151
- 152 Methods

153 Study design and participants

154 A total of 1,033 patients diagnosed with moderate-to-severe AS at the Second

- 155 Affiliated Hospital of Shantou University Medical College, the First Affiliated
- 156 Hospital of Sun Yat-sen University, or the Affiliated Hospital of Guangdong Medical
- 157 University were enrolled between January 2014 and July 2023. Three heart valve
- 158 centers are derived from a database called Aortic Valve Diseases RISk facTOr
- assessment and Prognosis modeL Construction (ARISTOTLE). The primary outcome
- 160 was all-cause mortality during the follow-up period. The inclusion criteria were as
- 161 follows: (1) moderate-to-severe AS (peak aortic jet velocity (Vmax) >3 m/s, mean
- aortic pressure gradient (MG) >20 mmHg, or aortic valve area (AVA) ≤ 1.5 cm²) on
- echocardiography, according to the 2021 European Society of Cardiology (ESC)/
- 164 European Association for Cardio Thoracic Surgery (EACTS) guidelines for the
- 165 management of valvular heart disease [9]; (2) congenital stenosis of the aortic valve;
- 166 (3) an initial diagnosis of aortic stenosis; and (4) no previous history of AVR. The
- exclusion criteria were as follows: (1) a history of aortic valve replacement; (2) severe
- 168 dysfunction or malignancy of other organs or systems; (3) connective tissue disease;
- (4) a ortic stenosis in combination with severe mitral stenosis; (5) malignant tumour;
- and (6) missing baseline data (N = 419). Ultimately, 544 patients with
- 171 moderate-to-severe AS remained for the analysis (Fig. 1).
- 172 The study was conducted according to the principles of the Declaration of

173 Helsinki and was approved by the Ethics Review Committee of the Shantou

174 University Medical College. All the data were collected from the hospital electronic

175 medical records, and follow-up was conducted through hospital visits or phone calls.

- 176 Verbal informed consent was obtained from the participants, as approved by the
- 177 Ethics Review Committee of the Second Affiliated Hospital of Shantou University
- **178** Medical College(ERB number: ethics form 9-5).

179 Data collection and definitions

180 Participants self-reported age, sex, height, body mass, smoking and alcohol

181 history, and medication upon admission. History of hypertension, diabetes, coronary

182 heart disease (CHD), atrial fibrillation, extra-cardiac artery lesions, or stroke was

183 further validated by medical professionals on the basis of blood test or imaging results.

184 Subsequent AVR surgery information was obtained from electronic medical records or

telephone interviews. BMI was calculated as body mass (kg)/height (m)2.

186 Hypertension was defined by antihypertensive drug use, systolic blood pressure ≥ 140

187 mmHg, or diastolic blood pressure \geq 90 mmHg. Chronic kidney disease (CKD) was

defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 using

189 CKD-EPI equation [20].

190 Laboratory tests within 24 hours of admission included white blood cell count,

191 haemoglobin, creatinine, uric acid, total cholesterol, low-density

192 lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C),

amino-terminal brain-natriuretic peptide precursor (NT-proBNP), and troponin. The

use of the following drugs was recorded: anti-platelet drugs, statins,

angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers

196 (ARBs), β -blockers, calcium channel blockers (CCBs), hypoglycaemic drugs, oral

197 anticoagulants, and diuretics. The following echocardiographic indices were also

- 198 recorded: left ventricular ejection fraction (LVEF), the maximum velocity of blood
- 199 passing through the aortic valve (AV_Vmax), the mean gradient across the aortic
- 200 valve (AV_MG), the aortic valve area (AVA), pulmonary arterial hypertension (PAH),
- 201 aortic regurgitation, mitral regurgitation, and mitral stenosis.
- 202 Definitions of echocardiographic indices
- 203 Transthoracic echocardiography followed American Society of Echocardiography
- 204 guidelines[21]. AS severity was defined as [3,4]: (1) moderate AS:
- 205 1 cm2<AVA≤1.5 cm2, 3 m/s<Vmax≤3.9 m/s, or <20 mm Hg<MG≤39 mm Hg; and (2)
- severe AS: AVA≤1 cm2, Vmax≥4 m/s, or MG≥40 mm Hg. PAH was defined as a
- 207 pulmonary arterial pressure ≥ 25 mm Hg, according to the Guidelines for the
- 208 Diagnosis and Treatment of Pulmonary Hypertension in China (2021 edition)[22].
- 209 Outcomes
- 210 The primary endpoint of the study was all-cause mortality from the time of the
- 211 diagnosis, whose information was collected by trained medical staff through
- telephone contact with the participants or their families. The secondary endpoints
- 213 were cardiovascular-related mortality and aortic stenosis-related mortality. The
- duration of follow-up was date of AS diagnosis to date of death or end of follow-up
- 215 Statistical analysis
- 216 Continuous datasets were tested for normality using the Shapiro–Wilk method, and
- 217 the data are presented as as mean \pm SD for normal distribution, or median and
- 218 interquartile range for skewed data. Categorical data are presented as counts and
- 219 percentages. Homogeneous datasets compared using ANOVA, heterogeneous using
- 220 Kruskal–Wallis test. $P \le 0.05$ was considered statistically significant. The participants
- 221 were allocated to high-risk or low-risk groups using a cut-off value of EUROSCORE
- 222 II of 4%, according to the 2017 ESC/EACTS guidelines[23]. Student's t-test or

ANOVA was used to evaluate differences between groups with respect to continuous

data, and Pearson's chi-square test or Fisher's exact test was used to compare

225 categorical datasets, as appropriate.

226 Kaplan–Meier method calculated cumulative survival, evaluated with log-rank 227 test. Cox proportional hazard analyses were performed, generating hazard ratios (HRs) 228 and 95% confidence intervals (CIs) for the relationships for EUROSCORE II and 229 AVR status association with all-cause mortality. Next, four multivariable models were 230 involved adjustment for potential confounders of all-cause mortality. Model 1 was 231 adjusted for smoking status, alcohol consumption status, diabetes, atrial fibrillation, 232 hypertension, gout, systolic blood pressure, and body mass. Model 2 was adjusted for 233 the parameters in model 1, with the addition of WBC, RBC, PLT, LDLC, TG, TBIL, 234 NTproBNP, troponin, and albumin. Model 3 was adjusted for the parameters in model 235 2, plus aortic valve deformity, rheumatic heart disease, AV-Vmax, AV-MG, the degree 236 of AVA mitral insufficiency, and mitral stenosis. Model 4 was adjusted for the 237 parameters in Model 3, with the addition of anti-platelet agent, statin, ACEI, ARB, 238 β-blocker, CCB, diuretic, insulin, oral antidiabetic drug, and oral anticoagulant use. 239 Further subgroup analyses were performed after the stratification of the participants 240 according to baseline sex, age (≤ 70 or >70 years), BMI (<24 or ≥ 24 kg/m²), diabetes, 241 hypertension, CHD, and the severity of AS (moderate or severe), to assess the 242 consistency of the prognostic use of EUROSCORE II for all-cause mortality. Finally, 243 the ROC curve was also used to determine the optimal cut-off value of EUROSCORE 244 II for the prediction of all-cause mortality in the participants. All analyses were 245 conducted in the IBM SPSS 26.0 statistical software and a two-sided P value<0.05 246 was considered statistically signifcant.

247

248

249 **Results**

- **250** Baseline characteristics of the participants
- 251
- 252 Clinical characteristics of the participants, stratified according to EUROSCORE II
- and AVR status
- A total of 1,033 patients who met the diagnostic criteria for AS were initially included
- in the study, but 70 were excluded because they fulfilled one of the exclusion criteria,
- 256 219 because of missing EUROSCORE II data, and 200 because of missing covariant
- data. Thus ultimately, data for 544 participants were analysed in the present study (Fig.

258 1), comprising 300 (55.2%) men and 244 (44.9%) women, with a mean age of

- 259 64.7±13.0 years. The baseline characteristics of the participants, after being
- 260 categorized according to the recommended cut-off value (4%) of EUROSCORE II

and whether or not AVR was performed, are shown in Table 1.

We evaluated the following six types of characteristics of the participants in the

263 four groups: their general characteristics, preoperative status assessment,

264 comorbidities, laboratory parameters, echocardiographic findings, and medical

265 therapy. Those with a EUROSCORE II index \geq 4% who did not undergo AVR surgery

tended to be older, have higher serum Cr, TBIL, and blood glucose concentrations, to

267 have a high NYHA score, and to have more comorbidities, such as diabetes and

268 hypertension, but to have a lower body mass and LDL-C and TG concentrations than

those in the other groups (all $P \le 0.05$). In addition, the echocardiographic findings

270 for the participants (Additional file Table S1) showed that the participants in this

- group were more likely to have other valvular diseases, severe PAH, and lower LVEF.
- 272 In addition, these participants were more likely to be administering statins, insulin,

- and oral anticoagulants. However, there were no differences among the four groups
- with respect to sex, their history of alcohol consumption or smoking, or in their oral
- anti-diabetic drug use (all *P*>0.05).
- 276 Baseline characteristics of the participants, stratified according to only
- 277 EUROSCORE II
- 278 During a follow-up period of 10.7 years, 132 (21.5%) participants had reached an
- endpoint. To evaluate the utility of EUROSCORE II alone for the prediction of
- all-cause mortality in patients with moderate-to-severe AS, we compared two groups
- of participants, categorized according to the recommended cut-off value (4%). As
- shown in Additional file Table S2, participants with higher EUROSCORE II (≥4%)
- were more likely to be female, older, require surgery more urgently, have more
- serious cardiac dysfunction and were more likely to have other heart valve diseases,
- such as mitral stenosis, mitral regurgitation, and aortic regurgitation. However, there
- were no significant differences between the groups with respect to the incidences of comorbidities (P>0.05).
- 288
- 289 Relationships of all-cause mortality with EUROSCORE II and AVR status
- 290

291 Results of the Kaplan–Meier analysis of the participants, stratified according to

292 both EUROSCORE II and AVR status

293 The log-rank test was employed to compare the cumulative survival of the groups of

294 participants, as depicted in Fig. 2. The analysis demonstrated that the participants in

- the group with high EUROSCORE II and who had not undergone AVR were at the
- highest risk of all-cause mortality of the four groups (log-rank P<0.001).

297 Results of the Kaplan–Meier analysis of the participants who had/hadn't

298 undergone AVR, stratified according to their EUROSCORE II

- 299 Compared with the low-risk group, the participants in the high-risk group showed
- 300 significantly poorer cumulative survival, according to the Kaplan–Meier curves
- 301 (*P*=0.001) (Additional File Fig. S1). Similar results were obtained for the participants
- 302 who had not undergone AVR (*P*=0.001) (Additional File Fig. S2).
- 303 Comparison of the Kaplan–Meier curves for participants who did or did not

304 *undergo AVR*

- **305** For the low-risk group of participants (EUROSCORE II <4%), the Kaplan–Meier
- 306 curves and the log-rank test showed that the cumulative survival time significantly
- 307 differed between those who had or had not undergone AVR (*P*=0.01) (Additional File
- **308** Fig. S3). Similarly, among high-risk participants (EUROSCORE II $\geq 4\%$), those who
- had not undergone AVR ($P \le 0.01$) (Additional File Fig. S4) showed significantly
- 310 poorer cumulative survival time than participants undergone AVR.
- However, there was no difference between those who underwent SAVR or TAVI
- **312** (*P*=0.692) (Additional File Fig. S5).
- 313

314 Predictors of all-cause mortality

- 315 The findings of the univariate and multivariate Cox regression analyses of the
- relationships of EUROSCORE II and AVR status with the all-cause mortality of the
- 317 participants are presented in Table 2. Univariate regression analysis showed that age,
- 318 CAD, CKD, COPD, diabetes, atrial fibrillation, hypertension, albumin, critical status,
- 319 urgency of surgery, EF, pulmonary hypertension, statin use, ACEI/ARB use, and
- 320 insulin use were predictors of all-cause mortality.
- 321 The univariate analysis showed that group 2 (EUROSCORE II <4%, without

322	AVR) were associated with a 5.97-fold higher risk than group 1 (EUROSCORE II
323	<4%, with AVR) (HR, 5.966; 95% CI 3.033–11.737; P<0.001). Furthermore,
324	participants in group 4 (EUROSCORE II \geq 4% and no AVR) were at a 12.17-fold
325	higher risk of all-cause mortality vs. those in group 1 (HR, 12.168; 95% CI
326	5.958–24.848; <i>P</i> <0.001).
327	Multivariate Cox regression analyses showed that group 1 (EUROSCORE II <4%,
328	had undergone AVR) exhibited the lowest risk (HR, 3.705, 95% CI 1.738–7.896,
329	P=0.001; and HR, 6.891, 95% CI 3.083–15.401, P<0.001 groups 2,4, respectively
330	compared with group 1).
331	However, there no significant difference between participants in group 3
332	(EUROSCORE II \geq 4% and AVR) and group 1 (HR, 1.368; 95% CI 0.627–2.984,
333	P=0.431). Notably, significant and more steady results were obtained after further
334	adjustment for potential confounders in Models 1-4 (Table 3). The fully adjusted HR
335	and 95% CI in Model 4 for groups 2–4 vs. group 1 were 3.492 (1.583–7.703), 1.333
336	(0.605–2.936), and 6.605 (2.817–15.486), respectively (P<0.05).
337	Moreover, participants in high risk without surgery (group 4) were further adjusted as
338	the reference to prove that, among high-risk participants (EUROSCORE II \geq 4%),
339	perform AVR (group 3) were associated with a 0.023-fold risk than without AVR
340	(group 4) (HR, 0.023; 95% CI 0.118-0.857, P<0.01).
341	
342	Results of the subgroup analyses
343	To further validate the identified difference in risk between participants who had or
344	had not undergone AVR, two subgroup analyses were performed to evaluate the
345	effects of relevant parameters on the relationship between EUROSCORE II and the

346 all-cause mortality of the participants. The participants were stratified according to

- 347 sex (male or female), age (≤ 70 or >70 years), diabetes (present or absent),
- 348 hypertension (present or absent), CHD (present or absent), severity of AS (moderate
- 349 or severe), aortic regurgitation (none, mild, moderate, or severe), LVEF (<40%,
- 40%-50%, or >50%), and the use of hypoglycaemic medication (yes or no).

351 Results of the subgroup analysis of the participants who had not undergone AVR

- 352 The results showed stronger associations between EUROSCORE II and the risk of
- all-cause mortality in younger (\leq 70 years old) male participants who did not have
- diabetes, hypertension, or CHD, were not taking hypoglycaemic medication, had mild
- aortic regurgitation, had an LVEF <40%, and had moderate aortic stenosis (Fig. 3).
- 356 The relationship of the EUROSCORE II index with all-cause mortality remained after
- adjustment for the confounders across all the subgroups, but there were no significant
- interactions between the subgroups (*P* for all interactions>0.05).

359 Results of the subgroup analysis of the participants who had undergone AVR

- 360 Analysis of the data for the participants who had undergone AVR (Additional file Fig.
- 361 S6) revealed a similar association between EUROSCORE II and the risk of all-cause
- 362 mortality risk in participants who did not have diabetes or CHD and were not taking
- 363 hypoglycaemic medication. None of the subgroups showed significant interactions (P
- for all interactions>0.05).
- 365

366 Optimal cut-off value of EUROSCORE II for the prediction of outcomes in the367 participants who had not undergone AVR

- 368 Fig. 4 shows the ROC curve analysis of the prognostic value of EUROSCORE II for
- the participants. The optimal cut-off value of EUROSCORE II identified for the
- 370 prediction of the primary outcome in the participants who had not undergone AVR
- 371 was 2.23%, which was associated with an AUC of 0.675 (95% CI: 0.609–0.74;

372 P<0.001). Therefore, the predictive value of a EUROSCORE II threshold of 2.23% 373 appears to be superior to that of 4% for the prediction of outcomes in patients without 374 AVR. 375 We also performed Kaplan–Meier analysis and Cox multivariate analysis to 376 confirm this finding. Kaplan-Meier analysis in supplemental Fig. S7 demonstrated 377 that participants with a EUROSCORE II >2.23% had a higher risk of all-cause 378 mortality than those with values <2.23% (log-rank, P<0.001). Additionally, compared 379 with the lower EUROSCORE II group, the higher EUROSCORE II (>2.23%) group 380 had a 2.111-fold higher risk of all-cause mortality (HR 2.111, 95% CI (1.069-4.166), 381 *P*=0.031), according to Cox multivariate analysis (Additional file Table S2). 382 383 Discussion

A growing body of evidence demonstrates that patients with symptomatic severe
aortic stenosis have a poor prognosis if they do not undergo surgery, with a mean
survival time of <4 years[8,24]. Therefore, AVR is widely recommended for the
treatment of such patients and is effective[24].

388 In the present study, we first explored the relationship between EUROSCORE II

and the long-term prognosis of patients with moderate-to-severe AS. We found that a

high EUROSCORE II is significantly associated with a higher risk of all-cause-

391 mortality in such patients and AVR could reduce death risk to that of patients with a

392 lower EUROSCORE II (<4%).

We first evaluated the long-term prognosis of patients who had received an initial

diagnosis of moderate-to-severe AS within the preceding 10 years, and found that

395 those with a EUROSCORE II \geq 4%, whether or not they have undergone AVR, have a

396 significantly higher risk of all-cause mortality than those with a EUROSCORE II

397 <4%. Many previous clinical studies have shown that the EUROSCORE II has 398 potential for use as a predictor of all-cause mortality for patients who undergo TAVI. 399 A retrospective study of 350 patients with at least moderate AS who underwent TAVI 400 showed that patients who died within 30 days had higher EUROSCORE II than those 401 survived (12.6±1.8 vs. 7.5±0.3%, P<0.001). This was associated with an AUC of 0.70, 402 which implies that EUROSCORE II is a good predictor of short-term mortality[25]. 403 Another study of data obtained from 59 patients with symptomatic severe aortic 404 stenosis who had undergone TAVI between 2010 and 2014 showed that 405 EUROSCORE II is a predictor of in-hospital mortality and 30-day mortality[26]. 406 However, the duration of follow-up in these studies was too short for the findings to 407 be highly relevant to clinical practice. However, a recent study by Fan et al. classified 408 332 patients with low-gradient severe aortic stenosis and the preservation of LVEF 409 into high-risk (EUROSCORE II \geq 4%, n=115) and low-risk (EUROSCORE II <4%, 410 n=208) groups and followed them over a 2-year period. They found that the 411 cumulative survival of the high-risk group was significantly poorer than that of the 412 low-risk group [27], which is consistent with the present findings that the use of 4% as 413 a cut-off value has some predictive value over a period of >2 years. 414 Kaplan-Meier analysis showed that patients who undergo SAVR or TAVI to treat 415 moderate-to-severe AS have comparable risks of relevant outcomes (P=0.692). This 416 finding is in general consistent with the results of some recent studies. One 417 prospective study of medium-term follow-up data from the Nordic Aortic Valve 418 Intervention (NOTION) trial, which was obtained for 280 patients at three centres in 419 Denmark and Sweden, showed that there was no difference in the all-cause mortality 420 associated with TAVR or SAVR after 2 years (8.0% and 9.8%, respectively; P=0.54) 421 or with respect to cardiovascular mortality (6.5% and 9.1%; P=0.40)[28]. In addition,

422 another study of data obtained during the NOTION trial also showed no significant
423 difference in the risk of all-cause mortality after 8 years of follow-up of these
424 patients[29].

425 In the present study, which involved a duration of follow-up of up to 10 years, we 426 also found evidence that patients with a low EUROSCORE II (<4%) should still be 427 recommended to undergo SAVR or TAVR (P=0.001) to have a good prognosis, 428 especially when there is some urgency in their condition. According to the 2021 429 ESC/EACTS guidelines for the management of valvular heart disease, SAVR is 430 recommended for patients <75 years old, while TAVR is recommended for older 431 patients (>75 years), high-risk patients (STS-PROM/EUROSCORE II >8%), and 432 those who are not eligible for surgery (class I)[9]. Despite this, many previous 433 randomized clinical trials have demonstrated that TAVR is non-inferior or even 434 superior to SAVR with respect to both short- and medium-term outcomes[30-37]. 435 Notably, the PARTNER2 study [40], the SURTAVI study [41], several studies of the 436 use of TAVR in low-risk patients performed by the American College of Cardiology 437 (ACC), including the PARTNER 3 study (using the SAPIEN-3 ultra transcatheter 438 heart valve) and the Evolut Low Risk Trial study (using the self-expanding Evolut R 439 valve)[42] showed that TAVR was associated with better than, or at least non-inferior, 440 results to, SAVR in low-risk patients. After the 5-year follow-up period, the Deep 441 Dive into the PARTNER 3 Five-Year Study showed that patients who undergo TAVR 442 or SAVR have similar annual incidences of cardiovascular-related mortality, stroke, 443 and re-hospitalization owing to cardiovascular disease (approximately 1%, 1%, and 444 3%, respectively). These findings are consistent with our conclusion that patients with 445 low EUROSCORE II (<4%) should still be recommended to undergo SAVR or TAVR. 446 Furthermore, some other studies have shown that SAVR and TAVR are safe and

447 effective, and are associated with a low risk of severe aortic stenosis, a low risk of

- 448 surgical complications, a short hospital stay, and a low risk of mortality during the
- 449 perioperative and 30-day postoperative periods[38-39].
- 450 Finally, the most appropriate cut-off value of EUROSCORE II to be used
- 451 prognostically varies according to the underlying disease, owing to the diversity in the
- 452 risk factors and pathophysiological mechanisms associated[43-44]. However, several
- 453 previous studies have shown that the use of EUROSCORE II is associated with an
- 454 underestimation of the risk of mortality for high-risk patients and an overestimation of
- 455 this risk for those with low levels of risk following various types of cardiac
- 456 surgery[43-49]. A previous study of 12,325 patients who underwent major cardiac
- 457 surgery showed that EUROSCORE II was a fairly accurate predictor up to a risk of
- 458 30%, but over-predicted outcomes above this level[50]. Furthermore, EUROSCORE
- 459 II was shown to be a fairly accurate predictor for octogenarians up to a risk level of
- 460 10%, but overestimated the risks above this level[49].
- 461 Although EUROSCORE II has been shown to be a good predictor of in-hospital
- 462 mortality following various types of surgery, the optimal cut-off values of
- 463 EUROSCORE II for the prediction of postoperative mortality were 10%–20%[51].
- 464 The present ROC curve analysis for EUROSCORE II showed that the most suitable
- 465 cut-off value for the prediction of outcomes in patients with moderate-to-severe AS
- 466 who had not undergone AVR was 2.23% (AUC, 0.675), rather than 4%. Therefore, we
- 467 next allocated the participants to a high EUROSCORE II group and a low
- 468 EUROSCORE II group using this cut-off value and compared their risks of outcomes.
- 469 Kaplan–Meier curve (log-rank P<0.001) and Cox multivariate (HR 2.111, 95% CI
- 470 (1.069–4.166), *P*=0.031) analyses were performed to provide further evidence that
- 471 2.23% is the optimal value to differentiate these groups of patients. It is worth

472 mentioning that the original value of 4% was used for patients with AS, whether or
473 not they had undergone surgery, whereas the 2.23% value calculated in the present
474 study is specific for patients with moderate-to-severe AS who have not undergone
475 AVR.

476 The major strength of the present study is that it was a multi-centre observational 477 study, the external validity of which could be verified. Furthermore, we followed the 478 participants for up to 10 years, which renders the results more reliable. We found a 479 significant association between EUROSCORE II and all-cause mortality in patients 480 with moderate-to-severe AS after comprehensive adjustment for potential confounders, 481 and made consistent findings in subgroup analyses. These findings should contribute 482 to the existing body of knowledge regarding the clinical utility of EUROSCORE II to 483 predict the outcomes of patients with AS, thereby leading to better outcomes and a 484 lower future burden of this valvular disease.

485

486 Limitations

487 The present study also had several limitations. First, the prediction of risk depends on 488 the accurate evaluation of each risk factor in EUROSCORE II, but the scores used are 489 based on European patients, rather than other groups. Therefore, the results need 490 further validation in studies of patients of other ethnicities. Second, although the 491 number of patients enrolled was relatively large and it was a multi-centre study, the 492 numbers were relatively low in comparison to the those accessible from a large 493 database, meaning that the analysis was relatively underpowered. Third, the 494 echocardiographic and laboratory parameters were only assessed once, at admission, 495 which may have resulted in bias owing to measurement errors or differences in 496 criteria between the centres. Finally, according to the 2021 ESC/EACTS guidelines,

497	SAVR should be recommended for younger patients with a low surgical risk (<75
498	years, STSPROM/EUROSCORE II <4%), while TAVR is recommended for older
499	patients (>75 years) and those at high risk (STS-PROM/EUROSCORE II >8%), but
500	we did not find a difference in the prognosis of the participants who underwent SAVR
501	or TAVI (P >0.05), which may be attributable to the limited sample size.
502	
503	Conclusions
504	We have shown for the first time that both EUROSCORE II and whether or not AVR
505	is performed are independently associated with the long-term prognosis of patients
506	with moderate-to-severe AS. Moreover, those who receive an initial diagnosis of
507	moderate-to-severe AS are recommended to undergo surgery (SAVR or TAVR) early
508	in their disease course, regardless of their EUROSCORE II. Finally, we have
509	identified an optimal EUROSCORE II cut-off value of 2.23% for the determination of
510	the prognosis of patients with moderate-to-severe AS who have not undergone AVR.
511	
512	
513	
514	
515	
516	
517	
518	
519	
520	
521	



Fig. 1. Flow diagram describing the study sample



- **Fig. 2.** Kaplan–Meier survival curves for the participants, categorized
- 530 according to their EUROSCORE II and their AVR status

Subgroups	Events/Total	HR(95%CI)	p value		p for interaction
Overall	84/218	2.075 (1.341-3.210) (-)	0.001		-
Sex					
Male	47/116	2.374 (1.292-4.362) (-)	0.005	• • • • • • • • • • • • • • • • • • •	
Female	37/102	2.171 (1.133-4.159) (-)	0.02		0.115
Age, years					
<=70	35/107	3.339 (1.630-6.841) (-)	0.001	• • • • • • • • • • • • • • • • • • •	
>70	49/111	1.528 (0.871-2.678) (-)	0.139		0.974
Diabetes					
Yes	27/47	1.550 (0.689-3.488) (-)	0.29		
No	57/171	2.401 (1.421-4.054) (-)	0.001		0.355
Hypertension					
Yes	46/120	1.808 (1.004-3.257) (-)	0.049		
No	38/98	2.527 (1.312-4.866) (-)	0.006	•	0.181
Coronary heart diseases					
Yes	24/53	1.0365 (0.409-2.626) (-)	0.94	_ _	
No	60/165	2.608 (1.568-4.338) (-)	<0.001	• • • • • • • • • • • • • • • • • • •	0.98
Aortic stenosis severity					
Moderate	51/127	2.512 (1.431-4.411) (-)	0.001	• • • • • • • • • • • • • • • • • • •	
High	33/91	1.631 (0.810-3.281) (-)	0.17		0.097
Aortic regurgitation					
Non	2/16.	3.464 (0.215-55.78) (-)	0.381	•	}
Mile	46/119	2.293 (1.282-4.101) (-)	0.005		0.949
Moderate	23/60	1.902 (0.777-4.658) (-)	0.159		0.928
Severe	13/23	1.896 (0.578-6.213) (-)	0.291		0.219
LVEF, %					
<40	10/19.	10.114 (1.198-85.37)	0.034)
40-50	12/21.	2.717 (0.818-9.025)	0.103	•	0.052
>50	62/178	1.587(0.932-2.705)	0.089	↓ ◆ →	0.301
Hypoglycemic medications					
No	71/186	2.352 (1.467-3.770) (-)	<0.001	↓	
Yes	13/32	0.995 (0.305-3.239) (-)	0.993		0.233
				00.2 1 2 3 4 5 6 Hzard Ratio(HR)	7

534 Fig. 3. Results of the subgroup analysis of the association between

- EUROSCORE II and the lack of AVR
- HR, hazard ratio; CI, confidence interval.





544 Fig. 4. ROC curve for the use of EUROSCORE II to evaluate the prognosis of545 the participants who had not undergone AVR

- ____

Table 1. Clinical characteristics of the participants, stratified according to their

559 EUROSCORE II and their AVR status

EUROSCO RE II	total (N=544) 4.58±4.99	Low risk with surgery (n=154) 2.32±1.06	Low risk without surgery (n=162) 1.89±0.89	High risk with surgery (n=172) 8.14±6.14	High risk without surgery (n=56) 7.66±6.2 3	P value <0.0 01
General cha	racteristics					
Hospital						
А	29 (5.33)	9 (5.84)	8 (4.94)	5 (2.91)	7 (12.50)	0.101
	454	124	138	146	46	
В	(83.46)	(80.52)	(85.19)	(84.88)	(82.14)	
С	61 (11.21)	21 (13.64)	16 (9.88)	21 (12.21)	3 (5.36)	
	64.69±12.	59.71±13.	67.58±11.	62.91±11.	75.48±11	<0.0
Age (years)	95	17	54	75	.44	01
Gender, n						
(%)						
	300	105	02(5(.70))	70 (45 02)	24	0.205
Male	(55.15)	(68.18)	92 (30.79)	79 (43.93)	(42.86)	0.393
	244	40 (21 82)	70 (42 21)	02(5407)	32	
Female	(44.85)	49 (31.82)	10 (43.21)	93 (J4.U7)	(57.14)	
	126.88±21	123.87±16	134.00±22	121.39±19	131.46±2	<0.0
SBP (mmHg) .24	.88	.98	.72	4.81	01

	59 26 11	60 60 10	50.51+11	56 09 10 7	55 05 11	<0.0
	38.30±11.	00.00±10.	39.31±11.	30.08±9.7	55.85±11	<0.0
Weight (kg)	07	97	73	9	.51	01
State assessme	ent					
Status at the						
first clinic						<0.0
visit						01
	518	154	162	159	43	
elective	(95.22)	(100.00)	(100.00)	(92.44)	(76.79)	
	26(4.78)	0 (0 00)	0 (0 00)	12 (7 56)	13	
urgent	20 (4.78)	0 (0.00)	0 (0.00)	15 (7.50)	(23.21)	
The urgency						<0.0
of the surgery						01
	264	70 (45 45)	146	6 (2,40)	42	
0	(48.53)	70 (43.43)	(90.12)	0 (3.49)	(75.00)	
	276	94 (54 55)	16 (0.99)	164	12	
non-CABG	(50.74)	64 (54.55)	10 (9.88)	(95.35)	(21.43)	
2	3 (0.55)	0 (0.00)	0 (0.00)	2 (1.16)	1 (1.79)	
3+	1 (0.18)	0 (0.00)	0 (0.00)	0 (0.00)	1 (1.79)	
NYHA(first						
						<0.0
visit)						01
	129	40 (25.07)	(28.27)	12 (7.56)	14	
	(23.71)	40 (23.97)	02 (38.27)	13 (7.30)	(25.00)	
	176	61 (11 56)	50 (26 42)	11 (75 50)	0(1607)	
II	(32.35)	04 (41.30)	JY (30.4 <i>2)</i>	44 (23.38)	9 (10.U/)	

medRxiv preprint doi: https://doi.org/10.1101/2024.08.23.24312516; this version posted August 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in percetuity.

It is made available unde	er a <mark>CC-B</mark>	SY 4.0 Internationa	I license .
---------------------------	------------------------	---------------------	-------------

	194				20	
III	(35.66)	46 (29.87)	36 (22.22)	92 (53.49)	(35.71)	
			5 (2.00)	22 (12 27)	13	
IV	45 (8.27)	4 (2.60)	5 (3.09)	23 (13.37)	(23.21)	
Comorbidities	5					
	213				33	<0.0
Hypertension	(39.15)	42 (27.27)	87 (53.70)	51 (29.65)	(58.93)	01
Rheumatic	00(1001)	25 (16 22)	26 (16.05)	26 (20, 02)	5 (9.02)	0 100
heart disease	92 (16.91)	25 (16.23)	26 (16.05)	36 (20.93)	5 (8.93)	0.199
Coronary	113				10	
disease	(20.77)	31 (20.13)	43 (26.54)	29 (16.86)	(17.86)	0.157
Previous	210			1.40		0.0
major cardiac	210	60 (38.96)	0 (0.00)	142	8 (14.29)	<0.0
surgery	(38.60)			(82.56)	01	
Atrial					16	
fibrillation	88 (16.18)	17 (11.04)	27 (16.67)	28 (16.28)		0.025
normation					(28.57)	
Stroke	36 (6.62)	6 (3.90)	18 (11.11)	6 (3.49)	(28.57) 6 (10.71)	0.010
Stroke CKD	36 (6.62) 33 (6.07)	6 (3.90) 4 (2.60)	18 (11.11) 11 (6.79)	6 (3.49) 10 (5.81)	(28.57) 6 (10.71) 8 (14.29)	0.010 0.018
Stroke CKD Extra-cardiac	36 (6.62) 33 (6.07)	6 (3.90) 4 (2.60)	18 (11.11) 11 (6.79)	6 (3.49) 10 (5.81)	(28.57) 6 (10.71) 8 (14.29) 11	0.010 0.018 < 0.0
Stroke CKD Extra-cardiac artery lesions	36 (6.62) 33 (6.07) 33 (6.07)	6 (3.90) 4 (2.60) 1 (0.65)	18 (11.11) 11 (6.79) 12 (7.41)	6 (3.49) 10 (5.81) 9 (5.23)	(28.57) 6 (10.71) 8 (14.29) 11 (19.64)	0.010 0.018 <0.0 01
Stroke CKD Extra-cardiac artery lesions COPD	36 (6.62) 33 (6.07) 33 (6.07) 22 (4.04)	6 (3.90) 4 (2.60) 1 (0.65) 4 (2.60)	18 (11.11) 11 (6.79) 12 (7.41) 8 (4.94)	6 (3.49) 10 (5.81) 9 (5.23) 3 (1.74)	 (28.57) 6 (10.71) 8 (14.29) 11 (19.64) 7 (12.50) 	0.010 0.018 <0.0 01 0.003
Stroke CKD Extra-cardiac artery lesions COPD diabetes	36 (6.62) 33 (6.07) 33 (6.07) 22 (4.04)	6 (3.90) 4 (2.60) 1 (0.65) 4 (2.60)	18 (11.11) 11 (6.79) 12 (7.41) 8 (4.94)	6 (3.49) 10 (5.81) 9 (5.23) 3 (1.74)	 (28.57) 6 (10.71) 8 (14.29) 11 (19.64) 7 (12.50) 14 	0.010 0.018 <0.0 01 0.003
Stroke CKD Extra-cardiac artery lesions COPD diabetes mellitus	36 (6.62) 33 (6.07) 33 (6.07) 22 (4.04) 82 (15.07)	6 (3.90) 4 (2.60) 1 (0.65) 4 (2.60) 18 (11.69)	18 (11.11) 11 (6.79) 12 (7.41) 8 (4.94) 33 (20.37)	6 (3.49) 10 (5.81) 9 (5.23) 3 (1.74) 17 (9.88)	 (28.57) 6 (10.71) 8 (14.29) 11 (19.64) 7 (12.50) 14 (25.00) 	0.010 0.018 <0.0 01 0.003 0.005
Stroke Stroke CKD Extra-cardiac artery lesions COPD diabetes mellitus History of	36 (6.62) 33 (6.07) 33 (6.07) 22 (4.04) 82 (15.07)	6 (3.90) 4 (2.60) 1 (0.65) 4 (2.60) 18 (11.69)	18 (11.11) 11 (6.79) 12 (7.41) 8 (4.94) 33 (20.37)	6 (3.49) 10 (5.81) 9 (5.23) 3 (1.74) 17 (9.88)	(28.57) 6 (10.71) 8 (14.29) 11 (19.64) 7 (12.50) 14 (25.00) 6 (10.71)	0.010 0.018 <0.0 01 0.003 0.005

History of	149	50 (32 47)	12 (26 51)	12 (24 12)	14	0.75
smoking	(27.39)	30 (32.47)	43 (20.34)	42 (24.42)	(25.00)	0.75
History of	04 (15 44)	2 <i>c</i> (1 <i>c</i> 0 0)	25 (15 42)	0.7 (1.5 70)		0.75
drinking	84 (15.44)	26 (16.88)	25 (15.43)	27 (15.70)	6(10.71)	0.75
Laboratory pa	arameters					
	124.34±22	129.36±21	123.80±22	123.18±22	115.63±2	0 001
HB	.40	.35	.73	.75	0.31	0.001
	7 61 2 46	7 77 - 7 24	7 55 2 17	<u> </u>	7.44±2.8	0.242
WBC	7.01±3.40	1.21±2.34	7.35±3.17	8.03±4.33	6	0.243
	155+126	4 65 1 22	4 72 + 1 25	4 40 + 1 08	4.23±1.2	0.01/
TC	4.35±1.20	4.05±1.55	4.75±1.55	4.40±1.08	4	0.014
	1 15 0 21	1 16 0 21	1 16 0 25	1 12 0 28	1.14±0.3	0.516
HDLC	1.15±0.51	1.10±0.51	1.10±0.55	1.12±0.28	0	0.310
	2 80 10 06	2 07 1 1 1	2.00+0.07	2 80 10 78	2.63±0.9	0.020
LDLC	2.89±0.90	2.97±1.11	2.99±0.97	2.80±0.78	8	0.039
	1 27+0 66	1 37+0 83	1 30+0 68	1 21+0 52	1.06±0.3	0 011
TG	1.27±0.00	1.37±0.85	1.30±0.08	1.21±0.32	7	0.011
	99.35±99.	81.78±25.	109.39±14	96.70±77.	126.79±1	0.012
Cr	48	66	6.74	60	10.33	0.012
	66.48±109	89.68±200	61.43±25.	58.95±22.	40.39±16	0.01
CC	.19	.12	92	90	.14	0.01
	7 22+4 14	6 30+2 23	7 31+5 18	7 49+4 12	8.65±4.4	0 002
UREA	/. <u>~~</u> +.1+	0.30-2.23	1.51±5.10	,, ⊤ ノ <u>'</u> + ,1∠	5	0.004
	16.43±17.	14.24±7.3	15.47±22.	17.96±15.	20.51±22	0.053
TBIL	05	0	36	18	.38	0.035

	Blood glucose	5.54±2.66	5.11±1.25	5.87±3.99	5.43±1.81	6.11±2.7 9	0.024
		38.17±5.2	39.46±5.2	37.38±5.2	38.12±4.8	37.07±6.	0 001
	Uric acid	4	1	2	0	05	0.001
	Elevated	275	64 (41 56)	91 (56 17)	80 (46 51)	40	<0.0
	NT-proBNP	(50.55)	0+ (+1.50))1 (30.17)	00 (+0.31)	(71.43)	01
	Troponin >	15 (2 76)	6 (3 90)	2 (1 23)	4 (2 33)	3 (5 36)	<0.0
	40	15 (2.70)	0 (3.90)	2 (1.23)	т (2.55)	5 (5.50)	01
560							
561							
562							
563							
564							
565							
566							
567							
568							
569							
570							
571							
572							
573							
574							
575							
576							

577 **Table 2.** Results of the univariate and multivariate Cox analyses of the

578 associations with EUROSCORE II and AVR status

	Univariate analysis	Р	multivariate analysis	Ρ
	HR(95% CI)	value	HR(<0.1,95% CI)	value
age	1.042(1.025-1.058)	0		
Male 0, female 1	0.956(0.664-1.376)	0.808		
SBP (mmHg)	1.008(1.000-1.016)	0.052	0.997(0.987-1.007)	0.545
Weight (kg)	0.984(0.967-1.002)	0.083	0.980(0.960-1.001)	0.067
Smoking	1.121(0.752-1.671)	0.576		
Drinking	0.902(0.539-1.509)	0.694		
Coronary disease	1.483(0.984-2.238)	0.06		
Myocardial infarction	2.360(1.150-4.843)	0.019		
Previous major cardiac	0 000/0 477 0 444)	0		
surgery	0.280(0.177-0.444)	0		
Stroke	2.728(1.607-4.629)	0	1.539(0.821-2.886)	0.179
СКD	3.183(1.873-5.408)	0	1.583(0.841-2.981)	0.155
Extra-cardiac artery		0.004		0.335
lesions	1.924(0.894-4.139)	0.094	0.669(0.296-1.513)	
COPD	1.710(0.833-3.510)	0.144		
Diabetes mellitus	2.052(1.340-3.144)	0.001	1.382(0.832-2.298)	0.212
Atrial fibrillation	1.802(1.189-2.731)	0.006	1.472(0.910-2.380)	0.115
Hypertension	1.496(1.040-2.152)	0.03	0.856(0.529-1.385)	0.527
Stroke	4.210(2.254-7.863)	0	2.334(1.158-4.703)	0.018

NYHA (first visit)		0.189		
	II	0.700(0.417-1.175)	0.177		
	Ш	1.082(0.675-1.737)	0.742		
	IV	1.290(0.640-2.600)	0.477		
Extraca	rdiac artery		0 700		
lesions		1.104(0.538-2.263)	0.788		
WBC		1.055(1.017-1.094)	0.004	1.056(1.013-1.100)	0.010
HB		0.988(0.981-0.995)	0.001		
PLT		0.998(0.996-1.001)	0.132		
тс		0.999(0.853-1.170)	0.99		
HDLC		0.705(0.371-1.340)	0.286		
LDLC		1.038(0.849-1.270)	0.715		
TG		0.702(0.488-1.010)	0.056	0.888(0.603-1.308)	0.547
TBIL		1.012(1.006-1.017)	0	1.013(1.006-1.020)	0.000
Blood gl	ucose	1.058(1.017-1.100)	0.005	1.022(0.964-1.085)	0.463
Uric acio	b	1.002(1.001-1.003)	0.005		
Elevated	d NT-proBNP	2.177(1.473-3.217)	0	1.314(0.851-2.029)	0.218
Troponii	n > 40	1.139(0.279-4.653)	0.856		
Albumin	I	0.915(0.885-0.946)	0	0.961(0.917-1.007)	0.097
Status a	t the first clinic	45 000(0 656 06 400)	0		
visit		15.992(9.656-26.486)	0		
The urg	ency of the	0 222/0 24 0 0 482)	0		
surgery		0.323(0.210-0.483)	U		
LVEF		0.983(0.969-0.996)	0.01		

Aortic valve bilobate				0.133
malformation	0.554(0.298-1.032)	0.063	0.608(0.318-1.164)	
AV_Vmax	0.799(0.632-1.009)	0.06	0.982(0.818-1.179)	0.843
AV_MG	0.991(0.980-1.001)	0.079	1.002(0.988-1.015)	0.824
AVA	0.909(0.476-1.738)	0.774		
РАН	1.538(1.173-2.017)	0.002		
Aortic regurgitation	0.960(0.772-1.194)	0.715		
Aortic stenosis	0.794(0.552-1.143)	0.214		
Mitral regurgitation	1.096(0.882-1.361)	0.409		
Mitral stenosis	1.042(0.870-1.248)	0.652		
Anti-plate medicine	1.267(0.867-1.851)	0.221		
Stains	1.788(1.237-2.583)	0.002	0.844(0.537-1.326)	0.462
ACEI/ARB	1.873(1.287-2.725)	0.001	1.374(0.878-2.150)	0.164
β-receptor blockers	1.149(0.798-1.655)	0.454		
ССВ	1.464(0.934-2.295)	0.096	1.171(0.692-1.982)	0.555
Diuretic drug	0.791(0.536-1.165)	0.235		
Insulin	2.430(1.484-3.979)	0		
Oral antidiabetic drug	1.045(0.597-1.829)	0.878		
Oral anticoagulants	0.383(0.258-0.567)	0	0.807(0.470-1.385)	0.436
Group		0		0.000
2	5.966(3.033-11.737)	0	3.705(1.738-7.896)	0.001
3	1.972(0.938-4.144)	0.073	1.368(0.627-2.984)	0.431
4	12.168(5.958-24.848)	0	6.891(3.083-15.401)	0.000

579 SBP, systolic blood pressure; CKD, chronic kidney disease; COPD, chronic

580 obstructive pulmonary disease; HB, haemoglobin; WC, waist circumference;

581	TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C,
582	low-density lipoprotein-cholesterol; TG, triglyceride; Cr, creatinine; CC,
583	creatinine clearance; TBIL, total bilirubin; LVEF, left ventricular ejection
584	fraction; AV_Vmax, maximum velocity of blood flow through the aortic valve;
585	AV_MG, mean gradient across the aortic valve; AVA, aortic valve area; PAH,
586	pulmonary arterial hypertension; ACEI, angiotensin converting enzyme
587	inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker.
588	
589 590	
591	
592	
593	
594	
595	
596	

- 597 **Table 3.** Relationships of EUROSCORE II and AVR status with the all-cause
- 598 mortality of the participants

	Low risk	Low risk	High risk	risk without	
variabl	with	without	with surgery	surgery	Р
es	surgery	surgery	(n=172)	(n=56)	
	(n=154)	(n=162)	()	(
Model	1	5.541(2.7	1.899(0.896-4.	10.058(4.632-2	<0.001
1	I	37-11.216)	025)	1.840)	<0.001
Model	4	4.211(2.05	1.450(0.673-3.	8.168(3.704-18	-0.001
2	I	3-8.637)	125)	.015)	<0.001

Model	1	4.064(1.9	1.321(0.605-2.	7.342(3.281-16	-0 001
3	I	58-8.433)	887)	.427)	<0.001
Model	1	3.492(1.5	1.333(0.605-2.	6.605(2.817-15	-0.001
4	I	83-7.703)	936)	.486)	<0.001

599	Model 1 was adjusted for smoking status, alcohol consumption status,
600	diabetes, atrial fibrillation, hypertension, gout, systolic blood pressure, and
601	body mass; Model 2 was adjusted for the parameters in model 1, with the
602	addition of WBC, RBC, PLT, LDLC, TG, TBIL, NTproBNP, troponin, and
603	albumin; Model 3 was adjusted for the parameters in model 2, plus aortic valve
604	deformity, rheumatic heart disease, AV-Vmax, AV-MG, the degree of AVA
605	mitral insufficiency, and mitral stenosis; Model 4 was adjusted for the
606	parameters in Model 3, with the addition of anti-platelet agent, statin, ACEI,
607	ARB, β -blocker, CCB, diuretic, insulin, oral antidiabetic drug, and oral
608	anticoagulant use.
609	
610	
611	
612	Legends
613	Fig. 1. Flow diagram describing the study sample
614	The study was performed at three heart valve centres: the Second Affiliated Hospital
615	of Shantou University Medical College, the First Affiliated Hospital of Sun Yat-sen
616	University, and the Affiliated Hospital of Guangdong Medical University. The
617	participants were allocated to high-risk or low-risk groups using a cut-off value of 4%
618	of EUROSCORE II. AVR Surgery, aortic valve replacement surgery. AS, aortic valve

619 stenosis.

- 620 Fig. 2. Kaplan–Meier survival curves for the participants, categorized according to
- 621 their EUROSCORE II and their AVR status
- 622 AVR, surgical aortic valve replacement or transcatheter aortic valve implantation.
- **623** Fig. 3. Results of the subgroup analysis of the association between EUROSCORE II
- and the lack of AVR
- 625 HR, hazard ratio; CI, confidence interval.
- **626** Fig. 4. ROC curve for the use of EUROSCORE II to evaluate the prognosis of the
- 627 participants who had not undergone AVR
- **628** Table 1. Clinical characteristics of the participants, stratified according to their
- 629 EUROSCORE II and their AVR status
- 630 Continuous variables are shown as median and IQR, and categorical variables are
- 631 shown as absolute number (n) and percentage. Continuous datasets were compared
- 632 using the Mann–Whitney test, and categorical datasets were compared using the
- 633 chi-square test or Fisher's exact test. A, Second Affiliated Hospital of Shantou
- 634 University Medical College; B, the First Affiliated Hospital of Sun Yat-sen University;
- 635 C, the Affiliated Hospital of Guangdong Medical University. SBP, systolic blood
- 636 pressure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary
- disease; HB, haemoglobin; WC, waist circumference; TC, total cholesterol; HDL-C,
- 638 high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; TG,
- triglyceride; Cr, creatinine; CC, creatinine clearance; TBIL, total bilirubin.
- 640 Table 2. Results of the univariate and multivariate Cox analyses of the associations
- 641 with EUROSCORE II and AVR status
- 642 SBP, systolic blood pressure; CKD, chronic kidney disease; COPD, chronic
- 643 obstructive pulmonary disease; HB, haemoglobin; WC, waist circumference; TC, total
- 644 cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density

- 645 lipoprotein-cholesterol; TG, triglyceride; Cr, creatinine; CC, creatinine clearance;
- 646 TBIL, total bilirubin; LVEF, left ventricular ejection fraction; AV_Vmax, maximum
- 647 velocity of blood flow through the aortic valve; AV_MG, mean gradient across the
- 648 aortic valve; AVA, aortic valve area; PAH, pulmonary arterial hypertension; ACEI,
- 649 angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB,
- 650 calcium channel blocker.
- **Table 3.** Relationships of EUROSCORE II and AVR status with the all-cause
- 652 mortality of the participants
- 653 Model 1 was adjusted for smoking status, alcohol consumption status, diabetes, atrial
- 654 fibrillation, hypertension, gout, systolic blood pressure, and body mass; Model 2 was
- adjusted for the parameters in model 1, with the addition of WBC, RBC, PLT, LDLC,
- 656 TG, TBIL, NTproBNP, troponin, and albumin; Model 3 was adjusted for the
- parameters in model 2, plus aortic valve deformity, rheumatic heart disease, AV-Vmax,
- AV-MG, the degree of AVA mitral insufficiency, and mitral stenosis; Model 4 was
- adjusted for the parameters in Model 3, with the addition of anti-platelet agent, statin,
- 660 ACEI, ARB, β -blocker, CCB, diuretic, insulin, oral antidiabetic drug, and oral
- anticoagulant use.
- 662
- 663



Fig. 1. Flow diagram describing the study sample



- 8 Fig. 2. Kaplan–Meier survival curves for the participants, categorized
- 9 according to their EUROSCORE II and their AVR status
- 10

7

Subgroups	Events/Total	HR(95%CI)	p value		p for interaction
Overall	84/218	2.075 (1.341-3.210) (-)	0.001		-
Sex					
Male	47/116	2.374 (1.292-4.362) (-)	0.005	• • • • • • • • • • • • • • • • • • •	
Female	37/102	2.171 (1.133-4.159) (-)	0.02		0.115
Age, years					
<=70	35/107	3.339 (1.630-6.841) (-)	0.001	• • • • • • • • • • • • • • • • • • •	
>70	49/111	1.528 (0.871-2.678) (-)	0.139		0.974
Diabetes					
Yes	27/47	1.550 (0.689-3.488) (-)	0.29		
No	57/171	2.401 (1.421-4.054) (-)	0.001		0.355
Hypertension					
Yes	46/120	1.808 (1.004-3.257) (-)	0.049		
No	38/98	2.527 (1.312-4.866) (-)	0.006	•	0.181
Coronary heart diseases					
Yes	24/53	1.0365 (0.409-2.626) (-)	0.94	_ _	
No	60/165	2.608 (1.568-4.338) (-)	<0.001	• • • • • • • • • • • • • • • • • • •	0.98
Aortic stenosis severity					
Moderate	51/127	2.512 (1.431-4.411) (-)	0.001	• • • • • • • • • • • • • • • • • • •	
High	33/91	1.631 (0.810-3.281) (-)	0.17		0.097
Aortic regurgitation					
Non	2/16.	3.464 (0.215-55.78) (-)	0.381	•	}
Mile	46/119	2.293 (1.282-4.101) (-)	0.005		0.949
Moderate	23/60	1.902 (0.777-4.658) (-)	0.159		0.928
Severe	13/23	1.896 (0.578-6.213) (-)	0.291		0.219
LVEF, %					
<40	10/19.	10.114 (1.198-85.37)	0.034)
40-50	12/21.	2.717 (0.818-9.025)	0.103	•	0.052
>50	62/178	1.587(0.932-2.705)	0.089	↓ ◆ →	0.301
Hypoglycemic medications					
No	71/186	2.352 (1.467-3.770) (-)	< 0.001	↓	
Yes	13/32	0.995 (0.305-3.239) (-)	0.993		0.233
				00.2 1 2 3 4 5 6 Hzard Ratio(HR)	7

13

- Fig. 3. Results of the subgroup analysis of the association between
- EUROSCORE II and the lack of AVR
- HR, hazard ratio; CI, confidence interval.



Fig. 4. ROC curve for the use of EUROSCORE II to evaluate the prognosis of the participants who had not undergone AVR

37 Table 1. Clinical characteristics of the participants, stratified according to their

38 EUROSCORE II and their AVR status

EUROSCO RE II	total (N=544) 4.58±4.99	Low risk with surgery (n=154) 2.32±1.06	Low risk without surgery (n=162) 1.89±0.89	High risk with surgery (n=172) 8.14±6.14	High risk without surgery (n=56) 7.66±6.2 3	P value <0.0 01
General chara	octeristics					
Hospital						
А	29 (5.33)	9 (5.84)	8 (4.94)	5 (2.91)	7 (12.50)	0.101
	454	124	138	146	46	
В	(83.46)	(80.52)	(85.19)	(84.88)	(82.14)	
С	61 (11.21)	21 (13.64)	16 (9.88)	21 (12.21)	3 (5.36)	
	64.69±12.	59.71±13.	67.58±11.	62.91±11.	75.48±11	<0.0
Age (years)	95	17	54	75	.44	01
Gender, n						
(%)						
	300	105	92 (56.79)	79 (45.93)	24	0.395
Male	(55.15)	(68.18)	,2 (00.77)	(10150)	(42.86)	0.070
	244	49 (31.82)	70 (43.21)	93 (54.07)	32	
Female	(44.85)	., (,	,	,	(57.14)	
	126.88±21	123.87±16	134.00±22	121.39±19	131.46±2	<0.0
SBP (mmHg)	.24	.88	.98	.72	4.81	01

	58.36±11.	60.60±10.	59.51±11.	56.08±9.7	55.85±11	<0.0
Weight (kg)	07	97	73	9	.51	01
State assessme	ent					
Status at the						
first clinic						<0.0
visit						01
	518	154	162	159	43	
elective	(95.22)	(100.00)	(100.00)	(92.44)	(76.79)	
	26(4.78)	0 (0 00)	0 (0 00)	12 (7 56)	13	
urgent	20 (4.78)	0 (0.00)	0 (0.00)	15 (7.50)	(23.21)	
The urgency						<0.0
of the surgery						01
	264	70 (45 45)	146	6 (2 10)	42	
0	(48.53)	70 (43.43)	(90.12)	0 (3.49)	(75.00)	
	276	84 (54 55)	16 (0.88)	164	12	
non-CABG	(50.74)	64 (54.55)	10 (9.88)	(95.35)	(21.43)	
2	3 (0.55)	0 (0.00)	0 (0.00)	2 (1.16)	1 (1.79)	
3+	1 (0.18)	0 (0.00)	0 (0.00)	0 (0.00)	1 (1.79)	
NYHA (first						<0.0
visit)						01
	129	40 (25.07)	(2)	12 (7.5.6)	14	
	(23.71)	40 (23.97)	02 (38.27)	13 (7.30)	(25.00)	
	176	CA (41 FC)	50 (26 42)	AA (05 50)	0 (1 < 07)	
II	(32.35)	04 (41.30)	JY (30.4 <i>2)</i>	44 (23.38)	9 (10.07)	

medRxiv preprint doi: https://doi.org/10.1101/2024.08.23.24312516; this version posted August 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a	CC-BY	4.0 International	license .
------------------------------	-------	-------------------	-----------

	101				• •	
	194	46 (29.87)	36 (22.22)	92 (53.49)	20	
III	(35.66)	× ,	· · · ·	· · · ·	(35.71)	
					13	
IV	45 (8.27)	4 (2.60)	5 (3.09)	23 (13.37)	(23.21)	
Comorbidities	5				× ,	
	213				33	~0.0
	215	42 (27.27)	87 (53.70)	51 (29.65)	55	<0.0
Hypertension	(39.15)				(58.93)	01
Rheumatic	02(1601)	25(1622)	26(16.05)	26(20.02)	5 (9.02)	0 100
heart disease	92 (10.91)	25 (10.25)	20 (10.05)	30 (20.93)	5 (8.95)	0.199
Coronary	113				10	
disease	(20.77)	31 (20.13)	43 (26.54)	29 (16.86)	(17.86)	0.157
	(20.77)				(17.00)	
Previous	210			142		<0.0
major cardiac	(38.60)	60 (38.96)	0 (0.00)	(82.56)	8 (14.29)	01
major cardiac surgery	(38.60)	60 (38.96)	0 (0.00)	(82.56)	8 (14.29)	01
major cardiac surgery Atrial	(38.60)	60 (38.96)	0 (0.00)	(82.56)	8 (14.29)	01
major cardiac surgery Atrial fibrillation	(38.60) 88 (16.18)	60 (38.96) 17 (11.04)	0 (0.00) 27 (16.67)	(82.56) 28 (16.28)	8 (14.29) 16 (28 57)	01 0.025
major cardiac surgery Atrial fibrillation	(38.60) 88 (16.18)	60 (38.96) 17 (11.04)	0 (0.00) 27 (16.67)	(82.56) 28 (16.28)	8 (14.29) 16 (28.57)	01 0.025
major cardiac surgery Atrial fibrillation Stroke	(38.60) 88 (16.18) 36 (6.62)	60 (38.96) 17 (11.04) 6 (3.90)	0 (0.00) 27 (16.67) 18 (11.11)	(82.56) 28 (16.28) 6 (3.49)	8 (14.29) 16 (28.57) 6 (10.71)	01 0.025 0.010
major cardiac surgery Atrial fibrillation Stroke CKD	(38.60) 88 (16.18) 36 (6.62) 33 (6.07)	60 (38.96) 17 (11.04) 6 (3.90) 4 (2.60)	0 (0.00) 27 (16.67) 18 (11.11) 11 (6.79)	(82.56) 28 (16.28) 6 (3.49) 10 (5.81)	8 (14.29) 16 (28.57) 6 (10.71) 8 (14.29)	01 0.025 0.010 0.018
major cardiac surgery Atrial fibrillation Stroke CKD Extra-cardiac	(38.60) 88 (16.18) 36 (6.62) 33 (6.07)	60 (38.96) 17 (11.04) 6 (3.90) 4 (2.60)	0 (0.00) 27 (16.67) 18 (11.11) 11 (6.79)	 (82.56) 28 (16.28) 6 (3.49) 10 (5.81) 	8 (14.29) 16 (28.57) 6 (10.71) 8 (14.29) 11	01 0.025 0.010 0.018 <0.0
major cardiac surgery Atrial fibrillation Stroke CKD Extra-cardiac artery lesions	(38.60) 88 (16.18) 36 (6.62) 33 (6.07) 33 (6.07)	60 (38.96) 17 (11.04) 6 (3.90) 4 (2.60) 1 (0.65)	0 (0.00) 27 (16.67) 18 (11.11) 11 (6.79) 12 (7.41)	(82.56) 28 (16.28) 6 (3.49) 10 (5.81) 9 (5.23)	8 (14.29) 16 (28.57) 6 (10.71) 8 (14.29) 11 (19.64)	01 0.025 0.010 0.018 <0.0 01
major cardiac surgery Atrial fibrillation Stroke CKD Extra-cardiac artery lesions COPD	(38.60) 88 (16.18) 36 (6.62) 33 (6.07) 33 (6.07) 22 (4.04)	60 (38.96) 17 (11.04) 6 (3.90) 4 (2.60) 1 (0.65) 4 (2.60)	0 (0.00) 27 (16.67) 18 (11.11) 11 (6.79) 12 (7.41) 8 (4.94)	 (82.56) 28 (16.28) 6 (3.49) 10 (5.81) 9 (5.23) 3 (1.74) 	8 (14.29) 16 (28.57) 6 (10.71) 8 (14.29) 11 (19.64) 7 (12.50)	01 0.025 0.010 0.018 <0.0 01 0.003
major cardiac surgery Atrial fibrillation Stroke CKD Extra-cardiac artery lesions COPD diabetes	(38.60) 88 (16.18) 36 (6.62) 33 (6.07) 33 (6.07) 22 (4.04)	60 (38.96) 17 (11.04) 6 (3.90) 4 (2.60) 1 (0.65) 4 (2.60)	0 (0.00) 27 (16.67) 18 (11.11) 11 (6.79) 12 (7.41) 8 (4.94)	 (82.56) 28 (16.28) 6 (3.49) 10 (5.81) 9 (5.23) 3 (1.74) 	8 (14.29) 16 (28.57) 6 (10.71) 8 (14.29) 11 (19.64) 7 (12.50) 14	01 0.025 0.010 0.018 <0.0 01 0.003
major cardiac surgery Atrial fibrillation Stroke CKD Extra-cardiac artery lesions COPD diabetes mellitus	 (38.60) 88 (16.18) 36 (6.62) 33 (6.07) 33 (6.07) 22 (4.04) 82 (15.07) 	60 (38.96) 17 (11.04) 6 (3.90) 4 (2.60) 1 (0.65) 4 (2.60) 18 (11.69)	0 (0.00) 27 (16.67) 18 (11.11) 11 (6.79) 12 (7.41) 8 (4.94) 33 (20.37)	 (82.56) 28 (16.28) 6 (3.49) 10 (5.81) 9 (5.23) 3 (1.74) 17 (9.88) 	8 (14.29) 16 (28.57) 6 (10.71) 8 (14.29) 11 (19.64) 7 (12.50) 14 (25.00)	01 0.025 0.010 0.018 <0.0 01 0.003
major cardiac surgery Atrial fibrillation Stroke CKD Extra-cardiac artery lesions COPD diabetes mellitus	 (38.60) 88 (16.18) 36 (6.62) 33 (6.07) 33 (6.07) 22 (4.04) 82 (15.07) 	60 (38.96) 17 (11.04) 6 (3.90) 4 (2.60) 1 (0.65) 4 (2.60) 18 (11.69)	0 (0.00) 27 (16.67) 18 (11.11) 11 (6.79) 12 (7.41) 8 (4.94) 33 (20.37)	 (82.56) 28 (16.28) 6 (3.49) 10 (5.81) 9 (5.23) 3 (1.74) 17 (9.88) 	8 (14.29) 16 (28.57) 6 (10.71) 8 (14.29) 11 (19.64) 7 (12.50) 14 (25.00)	01 0.025 0.010 0.018 <0.0 01 0.003 0.005
major cardiac surgery Atrial fibrillation Stroke CKD Extra-cardiac artery lesions COPD diabetes mellitus History of	 (38.60) 88 (16.18) 36 (6.62) 33 (6.07) 33 (6.07) 22 (4.04) 82 (15.07) 20 (3.68) 	60 (38.96) 17 (11.04) 6 (3.90) 4 (2.60) 1 (0.65) 4 (2.60) 18 (11.69) 1 (0.65)	0 (0.00) 27 (16.67) 18 (11.11) 11 (6.79) 12 (7.41) 8 (4.94) 33 (20.37) 10 (6.17)	 (82.56) 28 (16.28) 6 (3.49) 10 (5.81) 9 (5.23) 3 (1.74) 17 (9.88) 3 (1.74) 	8 (14.29) 16 (28.57) 6 (10.71) 8 (14.29) 11 (19.64) 7 (12.50) 14 (25.00) 6 (10.71)	01 0.025 0.010 0.018 <0.0 01 0.003 0.005

History of	149	50 (32 47)	13 (26 51)	12 (24 42)	14	0.75
smoking	(27.39)	50 (52.47)	43 (20.34)	42 (24.42)	(25.00)	0.75
History of	94 (15 44)	06 (16.00)	05 (15 42)	07 (15 70)	(10.71)	0.75
drinking	84 (15.44)	26 (16.88)	25 (15.43)	27 (15.70)	6(10.71)	0.75
Laboratory pa	arameters					
	124.34±22	129.36±21	123.80±22	123.18±22	115.63±2	
HB	.40	.35	.73	.75	0.31	0.001
					7.44±2.8	
WBC	7.61±3.46	7.27±2.34	7.55±3.17	8.03±4.55	6	0.243
					4.23±1.2	
ТС	4.55±1.26	4.65±1.33	4.73±1.35	4.40±1.08	4	0.014
					т 1 1 <i>1</i> +0 3	
	1.15±0.31	1.16±0.31	1.16±0.35	1.12±0.28	0	0.516
HDLC					0	
	2.89±0.96	2.97±1.11	2.99±0.97	2.80±0.78	2.63±0.9	0.039
LDLC					8	
	1.27±0.66	1.37±0.83	1.30±0.68	1.21±0.52	1.06±0.3	0.011
TG					7	
	99.35±99.	81.78±25.	109.39±14	96.70±77.	126.79±1	0.012
Cr	48	66	6.74	60	10.33	0.012
	66.48±109	89.68±200	61.43±25.	58.95±22.	40.39±16	0.01
CC	.19	.12	92	90	.14	0.01
					8.65±4.4	
UREA	7.22±4.14	6.30±2.23	7.31±5.18	7.49±4.12	5	0.002
	16.43±17.	14.24±7.3	15.47±22.	17.96±15.	20.51±22	
TBIL	05	0	36	18	.38	0.053

	Blood glucose	5.54±2.66	5.11±1.25	5.87±3.99	5.43±1.81	6.11±2.7 9	0.024
		38.17±5.2	39.46±5.2	37.38±5.2	38.12±4.8	37.07±6.	0 001
	Uric acid	4	1	2	0	05	0.001
	Elevated	275	64 (11 56)	01 (56 17)	90 (16 51)	40	<0.0
	NT-proBNP	(50.55)	04 (41.30)	91 (30.17)	80 (40.31)	(71.43)	01
	Troponin >			0 (1 00)	4 (2.22)		<0.0
	40	15 (2.76)	6 (3.90)	2 (1.23)	4 (2.33)	3 (5.36)	01
39							
40							
41							
42							
43							
44							
45							
46							
47							
48							
49							
50							
51							
52							
53							
54							
55							

56 Table 2. Results of the univariate and multivariate Cox analyses of the

57 associations with EUROSCORE II and AVR status

	Univariate analysis	Ρ	multivariate analysis	Р
	HR(95% CI)	value	HR(<0.1,95% CI)	value
age	1.042(1.025-1.058)	0		
Male 0, female 1	0.956(0.664-1.376)	0.808		
SBP (mmHg)	1.008(1.000-1.016)	0.052	0.997(0.987-1.007)	0.545
Weight (kg)	0.984(0.967-1.002)	0.083	0.980(0.960-1.001)	0.067
Smoking	1.121(0.752-1.671)	0.576		
Drinking	0.902(0.539-1.509)	0.694		
Coronary disease	1.483(0.984-2.238)	0.06		
Myocardial infarction	2.360(1.150-4.843)	0.019		
Previous major cardiac	0 200(0 477 0 444)	0		
surgery	0.280(0.177-0.444)	0		
Stroke	2.728(1.607-4.629)	0	1.539(0.821-2.886)	0.179
CKD	3.183(1.873-5.408)	0	1.583(0.841-2.981)	0.155
Extra-cardiac artery	4 004(0 004 4 400)	0.004		0.335
lesions	1.924(0.894-4.139)	0.094	0.669(0.296-1.513)	
COPD	1.710(0.833-3.510)	0.144		
Diabetes mellitus	2.052(1.340-3.144)	0.001	1.382(0.832-2.298)	0.212
Atrial fibrillation	1.802(1.189-2.731)	0.006	1.472(0.910-2.380)	0.115
Hypertension	1.496(1.040-2.152)	0.03	0.856(0.529-1.385)	0.527
Stroke	4.210(2.254-7.863)	0	2.334(1.158-4.703)	0.018
NYHA (first visit)		0.189		

	П	0.700(0.417-1.175)	0.177		
	Ш	1.082(0.675-1.737)	0.742		
	IV	1.290(0.640-2.600)	0.477		
	Extracardiac artery	1 104(0 529 2 262)	0 700		
	lesions	1.104(0.538-2.263)	0.788		
	WBC	1.055(1.017-1.094)	0.004	1.056(1.013-1.100)	0.010
	HB	0.988(0.981-0.995)	0.001		
	PLT	0.998(0.996-1.001)	0.132		
	тс	0.999(0.853-1.170)	0.99		
	HDLC	0.705(0.371-1.340)	0.286		
	LDLC	1.038(0.849-1.270)	0.715		
	TG	0.702(0.488-1.010)	0.056	0.888(0.603-1.308)	0.547
	TBIL	1.012(1.006-1.017)	0	1.013(1.006-1.020)	0.000
	Blood glucose	1.058(1.017-1.100)	0.005	1.022(0.964-1.085)	0.463
	Uric acid	1.002(1.001-1.003)	0.005		
Elevated NT-proBNP		2.177(1.473-3.217)	0	1.314(0.851-2.029)	0.218
	Troponin > 40	1.139(0.279-4.653)	0.856		
	Albumin	0.915(0.885-0.946)	0	0.961(0.917-1.007)	0.097
	Status at the first clinic	15 002(0 656 26 486)	0		
	visit	13.992(9.030-20.400)	0		
	The urgency of the	0 323/0 216-0 483)	0		
	surgery	0.323(0.210-0.403)	0		
	LVEF	0.983(0.969-0.996)	0.01		
	Aortic valve bilobate	0 554/0 208-1 022)	0 063		0.133
malformation		0.004(0.290-1.032)	0.003	0.608(0.318-1.164)	

AV_Vmax	0.799(0.632-1.009)	0.06	0.982(0.818-1.179)	0.843
AV_MG	0.991(0.980-1.001)	0.079	1.002(0.988-1.015)	0.824
AVA	0.909(0.476-1.738)	0.774		
РАН	1.538(1.173-2.017)	0.002		
Aortic regurgitation	0.960(0.772-1.194)	0.715		
Aortic stenosis	0.794(0.552-1.143)	0.214		
Mitral regurgitation	1.096(0.882-1.361)	0.409		
Mitral stenosis	1.042(0.870-1.248)	0.652		
Anti-plate medicine	1.267(0.867-1.851)	0.221		
Stains	1.788(1.237-2.583)	0.002	0.844(0.537-1.326)	0.462
ACEI/ARB	1.873(1.287-2.725)	0.001	1.374(0.878-2.150)	0.164
β-receptor blockers	1.149(0.798-1.655)	0.454		
ССВ	1.464(0.934-2.295)	0.096	1.171(0.692-1.982)	0.555
Diuretic drug	0.791(0.536-1.165)	0.235		
Insulin	2.430(1.484-3.979)	0		
Oral antidiabetic drug	1.045(0.597-1.829)	0.878		
Oral anticoagulants	0.383(0.258-0.567)	0	0.807(0.470-1.385)	0.436
Group		0		0.000
2	5.966(3.033-11.737)	0	3.705(1.738-7.896)	0.001
3	1.972(0.938-4.144)	0.073	1.368(0.627-2.984)	0.431
4	12.168(5.958-24.848)	0	6.891(3.083-15.401)	0.000

SBP, systolic blood pressure; CKD, chronic kidney disease; COPD, chronic 58

59 obstructive pulmonary disease; HB, haemoglobin; WC, waist circumference;

60 TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C,

61 low-density lipoprotein-cholesterol; TG, triglyceride; Cr, creatinine; CC,

62	creatinine clearance; TBIL, total bilirubin; LVEF, left ventricular ejection
63	fraction; AV_Vmax, maximum velocity of blood flow through the aortic valve;
64	AV_MG, mean gradient across the aortic valve; AVA, aortic valve area; PAH,
65	pulmonary arterial hypertension; ACEI, angiotensin converting enzyme
66	inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker.
67 68 69	
70	
71	
72	
73	
74	
75	

76 Table 3. Relationships of EUROSCORE II and AVR status with the all-cause

77 mortality of the participan

	Low risk	Low risk	High risk	risk without	
variabl	with	without		hok without	_
es	surgerv	surgerv	with surgery	surgery	Р
	((= ()	(())	(n=172)	(n=56)	
	(n=154)	(n=162)			
Model	4	5.541(2.7	1.899(0.896-4.	10.058(4.632-2	0.004
1	1	37-11.216)	025)	1.840)	<0.001
Model	1	4.211(2.05	1.450(0.673-3.	8.168(3.704-18	-0 001
2	1	3-8.637)	125)	.015)	<0.001
Model	1	4.064(1.9	1.321(0.605-2.	7.342(3.281-16	~0 001
3	·	58-8.433)	887)	.427)	\U.UU

Model	3.492(1.5	1.333(0.605-2.	6.605(2.817-15	
1				<0.001
4	83-7.703)	936)	.486)	

78	Model 1 was adjusted for smoking status, alcohol consumption status,
79	diabetes, atrial fibrillation, hypertension, gout, systolic blood pressure, and
80	body mass; Model 2 was adjusted for the parameters in model 1, with the
81	addition of WBC, RBC, PLT, LDLC, TG, TBIL, NTproBNP, troponin, and
82	albumin; Model 3 was adjusted for the parameters in model 2, plus aortic valve
83	deformity, rheumatic heart disease, AV-Vmax, AV-MG, the degree of AVA
84	mitral insufficiency, and mitral stenosis; Model 4 was adjusted for the
85	parameters in Model 3, with the addition of anti-platelet agent, statin, ACEI,
86	ARB, β -blocker, CCB, diuretic, insulin, oral antidiabetic drug, and oral
87	anticoagulant use.
88	
89	
90	
91	Legends
92	Fig. 1. Flow diagram describing the study sample
93	The study was performed at three heart valve centres: the Second Affiliated Hospital
94	of Shantou University Medical College, the First Affiliated Hospital of Sun Yat-sen
95	University, and the Affiliated Hospital of Guangdong Medical University. The
96	participants were allocated to high-risk or low-risk groups using a cut-off value of 4%
97	of EUROSCORE II. AVR Surgery, aortic valve replacement surgery. AS, aortic valve
98	stenosis.

99 Fig. 2. Kaplan–Meier survival curves for the participants, categorized according to

100 their EUROSCORE II and their AVR status

- 101 AVR, surgical aortic valve replacement or transcatheter aortic valve implantation.
- 102 Fig. 3. Results of the subgroup analysis of the association between EUROSCORE II
- and the lack of AVR
- 104 HR, hazard ratio; CI, confidence interval.
- **105** Fig. 4. ROC curve for the use of EUROSCORE II to evaluate the prognosis of the
- 106 participants who had not undergone AVR
- **107** Table 1. Clinical characteristics of the participants, stratified according to their
- **108** EUROSCORE II and their AVR status
- 109 Continuous variables are shown as median and IQR, and categorical variables are
- shown as absolute number (n) and percentage. Continuous datasets were compared
- 111 using the Mann–Whitney test, and categorical datasets were compared using the
- 112 chi-square test or Fisher's exact test. A, Second Affiliated Hospital of Shantou
- 113 University Medical College; B, the First Affiliated Hospital of Sun Yat-sen University;
- 114 C, the Affiliated Hospital of Guangdong Medical University. SBP, systolic blood
- 115 pressure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary
- disease; HB, haemoglobin; WC, waist circumference; TC, total cholesterol; HDL-C,
- 117 high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; TG,
- **118** triglyceride; Cr, creatinine; CC, creatinine clearance; TBIL, total bilirubin.
- **119** Table 2. Results of the univariate and multivariate Cox analyses of the associations
- 120 with EUROSCORE II and AVR status
- 121 SBP, systolic blood pressure; CKD, chronic kidney disease; COPD, chronic
- 122 obstructive pulmonary disease; HB, haemoglobin; WC, waist circumference; TC, total
- 123 cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density
- 124 lipoprotein-cholesterol; TG, triglyceride; Cr, creatinine; CC, creatinine clearance;
- 125 TBIL, total bilirubin; LVEF, left ventricular ejection fraction; AV_Vmax, maximum

- 126 velocity of blood flow through the aortic valve; AV MG, mean gradient across the
- aortic valve; AVA, aortic valve area; PAH, pulmonary arterial hypertension; ACEI,
- angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB,
- 129 calcium channel blocker.
- **Table 3.** Relationships of EUROSCORE II and AVR status with the all-cause
- **131** mortality of the participants
- 132 Model 1 was adjusted for smoking status, alcohol consumption status, diabetes, atrial
- 133 fibrillation, hypertension, gout, systolic blood pressure, and body mass; Model 2 was
- adjusted for the parameters in model 1, with the addition of WBC, RBC, PLT, LDLC,
- 135 TG, TBIL, NTproBNP, troponin, and albumin; Model 3 was adjusted for the
- 136 parameters in model 2, plus aortic valve deformity, rheumatic heart disease, AV-Vmax,
- AV-MG, the degree of AVA mitral insufficiency, and mitral stenosis; Model 4 was
- adjusted for the parameters in Model 3, with the addition of anti-platelet agent, statin,
- 139 ACEI, ARB, β -blocker, CCB, diuretic, insulin, oral antidiabetic drug, and oral
- 140 anticoagulant use.
- 141
- 142
- 143